Prof. Margaret Y. M. Lartey MBChB, MSc, MPH, FGCPS, FWACP

Dean, School of Medicine and Dentistry

School of Medicine and Dentistry of the University of Ghana

Professor Margaret Y. M Lartey is a Physician with specialist training and interests in Dermatology and Infectious Diseases. Her scholarly works have been mainly in Infectious Diseases with few in Dermatology even though she actively practiced both disciplines. Prior to becoming Dean, I was the Head of the Department for Medicine and Therapeutics for two years and Head of the Infectious Diseases Unit for 10 years as well of Head of the Dermatology Unit for 10 years.

My research areas include the skin and HIV, HIV Co-infections, Pharmacokinetics and Pharmacogenetics of Efavirenz in HIV and TB infected persons, HIV Drug Resistance, HIV-associated behavior (adherence, stigma, disclosure, employment, engagement with the health sector) and elimination of mother to child transmission (EMTCT). I have also researched various aspects of antiretroviral therapy. My research areas also include hepatitis, tuberculosis, cryptococcosis, rabies, Ebola, and tetanus. I have also researched aspects of pediatric and adolescent HIV infections.

In my work as an infectious disease physician, I supervise and train doctors, nurses, and other health workers in the clinical management of HIV infection cutting across adolescents and adults, pediatrics, MTCT, laboratory diagnoses, nutrition, counseling, and testing. I teach both undergraduate medical students, residents, and postgraduate students in the medical school and teaching hospital. I supervise Masters, Doctoral and post-doctoral students in allied disciplines. I have attended many local and international conferences, some of which I have made oral and poster presentations.

A few of my publications are presented below:

1. Archampong T.N.A., Boyce C.L., Lartey M., Sagoe K.W., Obo-Akwa A., Kenu E., Blackard J.T., Kwara A. (2016). HBV genotypes and drug resistance mutations in antiretroviral treatment-naïve and treatment-experienced HBV-HIV-co-infected patients. Anti Vir Ther; PMID: 27167598; doi: 10.3851/IMP3055.

2. Kwamena William Coleman Sagoe, Kwabena Obeng Duedu, Francesca Ziga, Afrakoma Adjoa Agyei, Theophilus Korku Adiku, Margaret Lartey, Julius Abraham Addo Mingle and Max Arens. Short-term treatment outcomes in human immunodeficiency virus type 1 and hepatitis B virus co-infections. Ann Clin Microbiol Antimicrob (2016) 15:38 DOI 10.1186/s12941-016-0152-

3. Daniel NA Ankrah, Ellen S Koster, Aukje K Mantel-Teeuwisse ,Daniel K Arhinful, Irene A Agyepong, Margaret Lartey. Facilitators and barriers to antiretroviral therapy adherence among adolescents in Ghana. Patient Preference and Adherence 2016:10 329–337

4. Edward K. Maina , C.Z. Abana , E.A. Bukusi , M. Sedegah , M. Lartey , W.K. Ampofo. Plasma concentrations of transforming growth factor beta 1in non-progressive HIV-1 infection correlate with markers of disease progression. Cytokine 81 (2016) 109–116

5. Archampong Timothy, Lartey Margaret, Sagoe Kwamena, Obo-Akwa Adjoa, Kenu Ernest, Gillani Fizza, Yang Hongmei, Boamah Isaac, Flanigan Timothy, Kwara Awewura. Proportion and factors associated with Hepatitis B viremia in antiretroviral treatment-naive and experienced HIV co-infected Ghanaian patients. BMC Infectious Diseases (2016) 16:14 DOI: 10.1186/s12879-016-1342-4

6. Ankrah DNA, Lartey M, Agyepong I, Hubert GM, Mantel-Teeuwisse AK (2015) Adherence and Treatment Change among HIV/AIDS Patients in Ghana – A Nested Case-Control Study. J AIDS Clin Res 6: 510. doi:10.4172/2155-6113.1000510

7. Margaret Lartey, Peter Puplampu, Nana Ayegua Hagan Seneadza, Joseph Oliver-Commey, Serwah Amoah, Sally-Ann Ohene. Preparing for Ebola, the experiences of a national training team (Ghana). Pan Afr Med J. 2015;22(Supp 1):12 DOI:10.11694/pamj.supp.2015.22.1.6320

8. E.K. Maina, E.Y. Bonney, E.A. Bukusi, M. Sedegah, M. Lartey, W.K. Ampofo. CD4+ T cell counts in the initiation of antiretroviral therapy in HIV infected asymptomatic individuals; controversies and inconsistencies, Immunol Lett (2015),

9. Stephanie Bjerrum, Ernest Kenu, Margaret Lartey, Mercy Jemina Newman, Kennedy Kwasi Addo, Aase Bengaard Andersen and Isik Somuncu Johansen. Diagnostic accuracy of the rapid urine lipoarabinomannan test for pulmonary tuberculosis among HIV-infected adults in Ghana–findings from the DETECT HIV-TB study. BMC Infectious Diseases (2015) 15:407

10. Nancy R. Reynolds, Angela Ofori-Atta, Margaret Lartey, Lorna Renner, Sampson Antwi, Anthony Enimil, Ann Christine Catlin, Sumudinie Fernando, Tassos C. Kyriakides and Elijah Paintsil. SANKOFA: a multisite collaboration on paediatric HIV disclosure in Ghana. AIDS 2015:29 (Suppl 1); S35–S45. DOI:10.1097/QAD.0000000000000725

11. M. Lartey, A. Asante-Quashie, A. Essel, E. Kenu, V. Ganu and A. Neequaye. Causes of death in hospitalized HIV patients in the early anti-retroviral therapy era. Ghana Med J 2015: 49 (1); 7-11. DOI: .

12. KP Akakpo, SE Quayson and M Lartey. Disseminated cryptococcosis in a patient with HIV/AIDS at a teaching hospital in Ghana. SAGE Open Medical Case Reports 2015. DOI: 10.1177/2050313X14565421

13. Awewura Kwara, Margaret Lartey, Isaac Boamah, ,Naser L. Rezk, Joseph Oliver-Commey, Ernest Kenu, ,Angela D. M. Kashuba, Michael H. Court. Interindividual Variability in Pharmacokinetics of Generic Nucleoside Reverse Transcriptase Inhibitors in TB/HIV-Coinfected Ghanaian Patients: UGT2B7*1c Is Associated With Faster Zidovudine Clearance and Glucuronidation. J. Clin. Pharmacol. 2009; 49; 1079-1090

14. Awewura Kwara, Margaret Lartey, Kwamena W Sagoe, Naser L Rzek, Michael H Court. CYP2B6 (c.516G>T) and CYP2A6 (*9B and/or *17) Polymorphisms are Independent Predictors of Efavirenz Plasma Concentrations in HIV-infected Patients.Br J Clin Pharmacol 2009; 67:4,427-436

15. Kwara A, Lartey M, Sagoe KWC, Xexemeku F, Kenu E, Oliver-Commey J, Boima V, Sagoe A, Boamah I, Greenblatt DJ, Court MH. Pharmacokinetics of Efavirenz When Co-Administered With Rifampin in TB/HIV Co-Infected Patients: Pharmacogenetic Effect of CYP2B6 Variation. J Clin Pharmacol 2008;48:1032-1040


Medical Training & Practice Conference - 2022 (Day 1)

See Facilitators Directory